About Virogentics
Virogentics is a company based in Dallas (United States) founded in 2021. It operates as a D2C. Virogentics offers products and services including IPF Technology and Antiviral Peptide. Virogentics operates in a competitive market with competitors including Science In Sport, Healthycell, Innate Response, Immuno Gum and Tonic Health, among others.
- Headquarter Dallas, United States
- SectorsHealthcare
- Website virogenticsinc.com
- Social X
- Legal Name Virogentics, Inc
Products & Services of Virogentics
Virogentics offers a comprehensive portfolio of products and services, including IPF Technology and Antiviral Peptide.
Patented peptide for broad-spectrum antiviral activity and immune support.
Based on IPF technology, targets viruses like influenza and HIV effectively.
Competitors of Virogentics
Virogentics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Science In Sport, Healthycell, Innate Response, Immuno Gum and Tonic Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scienceinsport.com | 1992 | Manly, Australia | – | – | Sports nutrition and vitamin products are provided by the brand. | |
| healthycell.com | 2012 | Montclair, United States | $1.57M | 7 | Branded cellular nutrition supplements are manufactured and marketed. | |
| innateresponse.com | 1973 | Derry, United States | – | 216 | Plant-based supplements are developed to support innate healing processes. | |
| immuno-gum.com | 2011 | Orange, United States | $1.25M | – | Immune-boosting ingredients are delivered via chewing gum. | |
| tonichealth.co | 2019 | London, United Kingdom | $608,975 | 2 | Nutritional supplements and plant-powered vitamin drinks are manufactured. | |
| prosymbiotics.com | 1996 | Irvine, United States | – | – | A range of colostrum-based health supplements is manufactured and marketed. | |
| inovacenutrition.com | 2022 | Surat, India | – | – | Nutritional supplements are developed to support health and wellness. | |
| mannax.ca | 2012 | Tecumseh, Canada | – | 1 | Provides dietary supplements to enhance physical and mental well-being. | |
| sunchlorella.com | 1969 | Torrance, United States | – | – | Offers a fully integrated solution for manufacturing and marketing algae-based health supplements. |
Detailed competitors of Virogentics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Virogentics
Complete news archive for Virogentics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Virogentics
10 companies that operate in the same segment as Virogentics (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Virogentics
Virogentics was founded in 2021.
Virogentics is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Virogentics focuses on creating patented antiviral peptides using Inactivated Pepsin Fragment technology. This innovation has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria, showing potential against viruses like influenza and HIV. The company offers products through an online shop, targeting consumers and possibly researchers. Activities include technology development, clinical testing, and sales of immune support solutions, with ongoing research for new viral treatments.
Virogentics's top competitors include Science In Sport, Healthycell and Innate Response.
Virogentics offers IPF Technology and Antiviral Peptide.
Virogentics operates through Virogentics, Inc.